Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Оценена ли роль трастузумаба в адъювантном режиме? Результаты 2-летнего периода наблюдения за пациентками с HER2-положительным раком молочной железы, получавшими трастузумаб в адъювантном режиме после завершения химиотерапии
Оценена ли роль трастузумаба в адъювантном режиме? Результаты 2-летнего периода наблюдения за пациентками с HER2-положительным раком молочной железы, получавшими трастузумаб в адъювантном режиме после завершения химиотерапии
Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Аннотация
Реферат
Полный текст
Список литературы
1. Gschwind A, Fischer OM, Ullrich A. The discovery of receptor tyrosine kinases: targets for cancer therapy. Nat Rev Cancer 2004; 4: 361–70.
2. Slamon DJ, Clark GM, Wong SG et al. Human breast cancer: correlation of relapse and survival with amplifi cation of the HER-2/neu oncogene. Science 1987; 235: 177–82.
3. Slamon DJ, Godolphin W, Jones LA et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989; 244: 707–12.
4. Vogel CL, Cobleigh MA, Tripathy D et al. Effi cacy and safety of trastuzumab as a single agent in fi rst-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 2002; 20: 719–26.
5. Baselga J, Carbonell X, Castaneda-Soto NJ et al. Phase II study of effi cacy, safety, and pharmacokinetics of trastuzumab monotherapy administered on a 3-weekly schedule. J Clin Oncol 2005; 23: 2162–71.
6. Slamon DJ, Leyland-Jones B, Shak S et al. Concurrent administration of anti-HER2 monoclonal antibody and fi rst-line chemotherapy for HER2-overexpressing metastatic breast cancer. A phase III, multinational, randomised controlled trial. N Engl J Med 2001; 344: 783–92.
7. Marty M, Cognetti F, Maraninchi D et al. Randomised phase II trial of the effi cacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as fi rst-line treatment: the M77001 Study Group. J Clin Oncol 2005; 23: 4265–74.
8. Piccart-Gebhart MJ, Procter M, Leyland-Jones B et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005; 353: 1659–72.
9. Romond EH, Perez EA, Bryant J et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005; 353: 1673–84.
10. Slamon D, Eiermann W, Robert N et al. Phase III randomised trial comparing doxorubicin and cyclophosphamide followed by docetaxel (AC T) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (AC TH) with docetaxel, carboplatin and trastuzumab (TCH) in HER2 positive early breast cancer patients: BCIRG 006 study. 28th Annual San Antonio Breast Cancer Symposium; San Antonio, TX, USA; Dec 7–10, 2005. (Abstr 1).
11. Joensuu H, Kellokumpu-Lehtinen PL, Bono P et al. Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N Engl J Med 2006; 354: 809–20.
12. The Lancet. Herceptin and early breast cancer: a moment for caution. Lancet 2005; 366: 1673.
13. HERA Study Team. Trastuzumab (H: Herceptin®) following adjuvant chemotherapy (CT) signifi cantly improves disease-free survival (DFS) in early breast cancer (BC) with HER2 overexpression: the HERA Trial. 28th Annual San Antonio Breast Cancer Symposium; San Antonio, TX, USA; Dec 7–10, 2005. (Abstr 11).
14. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005; 365: 1687–717.
15. Bonadonna G, Brusamolino E, Valagussa P et al. Combination chemotherapy as an adjuvant treatment in operable breast cancer. N Engl J Med 1976; 294: 405–10.
16. Baum M, Budzar AU, Cuzick J et al. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet 2002; 359: 2131–39.
17. Coombes RC, Hall E, Gibson LJ et al. A randomized trial of exemestane after two or three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med 2004; 350: 1081–92.
18. Thurlimann B, Keshaviah A, Coates AS et al. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med 2005; 353: 2747–57.
19. Baum M, Brinkley DM, Dossett JA et al. Improved survival among patients treated with adjuvant tamoxifen after mastectomy for early breast cancer. Lancet 1983; 2: 450.
20. Hortobagyi GN. Trastuzumab in the treatment of breast cancer. N Engl J Med 2005; 353: 1734–36.
21. Tan-Chiu E, Yothers G, Romond E et al. Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer. NSABP B-31. J Clin Oncol 2005; 23: 7811–9.
22. Guarneri V, Lenihan DJ, Valero V et al. Long-term cardiac tolerability of trastuzumab in metastatic breast cancer: the MD Anderson Cancer Center experience. J Clin Oncol 2006; 24: 4107–15.
23. Perez EA, Suman VJ, Davidson N et al. Advances in monoclonal therapy for breast cancer: further analysis of NCCTG N9831. 41st Annual Meeting of the American Society of Clinical Oncology; Orlando, FL; May 16, 2005.
2. Slamon DJ, Clark GM, Wong SG et al. Human breast cancer: correlation of relapse and survival with amplifi cation of the HER-2/neu oncogene. Science 1987; 235: 177–82.
3. Slamon DJ, Godolphin W, Jones LA et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989; 244: 707–12.
4. Vogel CL, Cobleigh MA, Tripathy D et al. Effi cacy and safety of trastuzumab as a single agent in fi rst-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 2002; 20: 719–26.
5. Baselga J, Carbonell X, Castaneda-Soto NJ et al. Phase II study of effi cacy, safety, and pharmacokinetics of trastuzumab monotherapy administered on a 3-weekly schedule. J Clin Oncol 2005; 23: 2162–71.
6. Slamon DJ, Leyland-Jones B, Shak S et al. Concurrent administration of anti-HER2 monoclonal antibody and fi rst-line chemotherapy for HER2-overexpressing metastatic breast cancer. A phase III, multinational, randomised controlled trial. N Engl J Med 2001; 344: 783–92.
7. Marty M, Cognetti F, Maraninchi D et al. Randomised phase II trial of the effi cacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as fi rst-line treatment: the M77001 Study Group. J Clin Oncol 2005; 23: 4265–74.
8. Piccart-Gebhart MJ, Procter M, Leyland-Jones B et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005; 353: 1659–72.
9. Romond EH, Perez EA, Bryant J et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005; 353: 1673–84.
10. Slamon D, Eiermann W, Robert N et al. Phase III randomised trial comparing doxorubicin and cyclophosphamide followed by docetaxel (AC T) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (AC TH) with docetaxel, carboplatin and trastuzumab (TCH) in HER2 positive early breast cancer patients: BCIRG 006 study. 28th Annual San Antonio Breast Cancer Symposium; San Antonio, TX, USA; Dec 7–10, 2005. (Abstr 1).
11. Joensuu H, Kellokumpu-Lehtinen PL, Bono P et al. Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N Engl J Med 2006; 354: 809–20.
12. The Lancet. Herceptin and early breast cancer: a moment for caution. Lancet 2005; 366: 1673.
13. HERA Study Team. Trastuzumab (H: Herceptin®) following adjuvant chemotherapy (CT) signifi cantly improves disease-free survival (DFS) in early breast cancer (BC) with HER2 overexpression: the HERA Trial. 28th Annual San Antonio Breast Cancer Symposium; San Antonio, TX, USA; Dec 7–10, 2005. (Abstr 11).
14. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005; 365: 1687–717.
15. Bonadonna G, Brusamolino E, Valagussa P et al. Combination chemotherapy as an adjuvant treatment in operable breast cancer. N Engl J Med 1976; 294: 405–10.
16. Baum M, Budzar AU, Cuzick J et al. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet 2002; 359: 2131–39.
17. Coombes RC, Hall E, Gibson LJ et al. A randomized trial of exemestane after two or three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med 2004; 350: 1081–92.
18. Thurlimann B, Keshaviah A, Coates AS et al. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med 2005; 353: 2747–57.
19. Baum M, Brinkley DM, Dossett JA et al. Improved survival among patients treated with adjuvant tamoxifen after mastectomy for early breast cancer. Lancet 1983; 2: 450.
20. Hortobagyi GN. Trastuzumab in the treatment of breast cancer. N Engl J Med 2005; 353: 1734–36.
21. Tan-Chiu E, Yothers G, Romond E et al. Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer. NSABP B-31. J Clin Oncol 2005; 23: 7811–9.
22. Guarneri V, Lenihan DJ, Valero V et al. Long-term cardiac tolerability of trastuzumab in metastatic breast cancer: the MD Anderson Cancer Center experience. J Clin Oncol 2006; 24: 4107–15.
23. Perez EA, Suman VJ, Davidson N et al. Advances in monoclonal therapy for breast cancer: further analysis of NCCTG N9831. 41st Annual Meeting of the American Society of Clinical Oncology; Orlando, FL; May 16, 2005.
Авторы
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.